Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1462512
This article is part of the Research Topic Novel Biomarkers in Solid Tumors and Related Medicine Therapy View all 6 articles

Diagnostic lncRNA High expression for liver patients Prognosis and medication guidance: a systematic review and meta-analysis

Provisionally accepted
Hengzhou Zhu Hengzhou Zhu *Haoyan Chen Haoyan Chen Xiaodan Zhu Xiaodan Zhu Baonan Zhang Baonan Zhang Chunhui Jin Chunhui Jin *
  • Wuxi Traditional Chinese Medicine Hospital, Wuxi, China

The final, formatted version of the article will be published soon.

    The study of long non-coding RNAs (lncRNAs) has gained significant attention due to their roles in regulating gene expression and their potential as diagnostic biomarkers. This systematic review and meta-analysis aimed to evaluate the diagnostic value of high-expression lncRNAs in liver disease patients, including those with hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).Methods: A comprehensive literature search was conducted across multiple electronic databases, including PubMed, Embase, Web of Science, and Cochrane Library, up to July 2024. Studies were included if they investigated the expression of lncRNAs in liver disease patients and evaluated their diagnostic performance. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was used to assess the quality of included studies. Pooled sensitivity, specificity, diagnostic odds ratios (DOR), and summary receiver operating characteristic (SROC) curves were calculated using a bivariate random-effects model.Nine studies involving 888 samples were included in the meta-analysis. The pooled hazard ratio (HR) for overall survival (OS) was 2.01 (95% CI: 1.71 to 2.36), indicating a significant association between high lncRNA expression and poor liver disease outcomes. Subgroup analyses revealed a pooled odds ratio (OR) of 1.99 (95% CI: 1.53 to 2.60) for tissue samples and 8.62 (95% CI: 1.16 to 63.71) for blood samples, suggesting a stronger diagnostic value for blood-based lncRNAs. The funnel plots indicated minimal publication bias, and sensitivity analyses confirmed the robustness of the findings.High-expression lncRNAs show significant potential as diagnostic biomarkers for liver diseases, offering non-invasive, accurate, and timely diagnostic information. Despite the promising results, further research is needed to standardize detection methods, elucidate the biological functions of lncRNAs, and validate their clinical utility in diverse patient populations. Integrating lncRNA biomarkers with traditional diagnostic approaches could enhance diagnostic accuracy and improve patient management and outcomes in liver disease.

    Keywords: Long non-coding RNAs (lncRNAs), Liver Diseases, biomarkers, diagnosis, Meta-analysis

    Received: 10 Jul 2024; Accepted: 31 Jul 2024.

    Copyright: © 2024 Zhu, Chen, Zhu, Zhang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hengzhou Zhu, Wuxi Traditional Chinese Medicine Hospital, Wuxi, China
    Chunhui Jin, Wuxi Traditional Chinese Medicine Hospital, Wuxi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.